Rachel Schiff

List of Publications by Year
in descending order

98 papers	8,238 citations	53794 45 h-index	48315 88 g-index
99 all docs	99 docs citations	99 times ranked	11881 citing authors

#	Article	IF	Citations
1	Mechanisms of Endocrine Resistance in Breast Cancer. Annual Review of Medicine, 2011, 62, 233-247.	12.2	963
2	ESR1 mutationsâ€"a mechanism for acquired endocrine resistance in breast cancer. Nature Reviews Clinical Oncology, 2015, 12, 573-583.	27.6	458
3	Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase. Journal of Clinical Oncology, 2005, 23, 2469-2476.	1.6	436
4	HER2: Biology, Detection, and Clinical Implications. Archives of Pathology and Laboratory Medicine, 2011, 135, 55-62.	2.5	404
5	Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance. Clinical Cancer Research, 2004, 10, 331s-336s.	7.0	397
6	A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models. Cancer Research, 2013, 73, 4885-4897.	0.9	394
7	Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2â€"Overexpressing Breast Cancer: TBCRC 006. Journal of Clinical Oncology, 2013, 31, 1726-1731.	1.6	238
8	Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivation. Breast Cancer Research, 2011, 13, R121.	5.0	219
9	Targeting HER2 for the Treatment of Breast Cancer. Annual Review of Medicine, 2015, 66, 111-128.	12.2	213
10	HER2: biology, detection, and clinical implications. Archives of Pathology and Laboratory Medicine, 2011, 135, 55-62.	2.5	189
11	Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clinical Cancer Research, 2003, 9, 447S-54S.	7.0	182
12	Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy. Journal of the National Cancer Institute, 2007, 99, 694-705.	6.3	176
13	Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemotherapy and Pharmacology, 2005, 56, 10-20.	2.3	170
14	Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. Cancer Research, 2018, 78, 845-852.	0.9	169
15	Towards personalized treatment for early stage HER2-positive breast cancer. Nature Reviews Clinical Oncology, 2020, 17, 233-250.	27.6	166
16	An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Research, 2014, 24, 809-819.	12.0	155
17	Î²1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Research, 2011, 13, R84.	5.0	147
18	Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts. Cancer Research, 2008, 68, 7493-7501.	0.9	120

#	Article	IF	Citations
19	FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6600-E6609.	7.1	119
20	Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. Breast Care, 2013, 8, 256-262.	1.4	117
21	Recurrent ESR1â€“CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nature Communications, 2014, 5, 4577.	12.8	112
22	Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Research, 2016, 76, 6495-6506.	0.9	105
23	FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26823-26834.	7.1	103
24	The changing role of ER in endocrine resistance. Breast, 2015, 24, S60-S66.	2.2	97
25	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. Journal of the National Cancer Institute, 2020, 112, 46-54.	6.3	97
26	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2020, 84, 101965.	7.7	92
27	HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clinical Cancer Research, 2017, 23, 5123-5134.	7.0	85
28	Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance. Nature Cell Biology, 2020, 22, 701-715.	10.3	84
29	Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4482-E4491.	7.1	83
30	Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clinical Cancer Research, 2015, 21, 3995-4003.	7.0	82
31	The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer. Current Oncology Reports, 2017, 19, 35.	4.0	80
32	Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2â€“ERÎ±â€“GREB1 Transcriptional Axis. Cancer Research, 2018, 78, 671-684.	0.9	80
33	Sub-100nm gold nanomatryoshkas improve photo-thermal therapy efficacy in large and highly aggressive triple negative breast tumors. Journal of Controlled Release, 2014, 191, 90-97.	9.9	79
34	Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. Npj Breast Cancer, 2018, 4, 38.	5.2	78
35	Microscaled proteogenomic methods for precision oncology. Nature Communications, 2020, 11, 532.	12.8	78
36	Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts. Clinical Cancer Research, 2011, 17, 1351-1361.	7.0	76

#	Article	IF	Citations
37	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Research and Treatment, 2018, 167, 731-740.	2.5	71
38	Pathway-Centric Integrative Analysis Identifies RRM2 as a Prognostic Marker in Breast Cancer Associated with Poor Survival and Tamoxifen Resistance. Neoplasia, 2014, 16, 390-402.	5.3	66
39	Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle, 2015, 14, 648-655.	2.6	66
40	Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance. Nature Communications, 2019, 10, 1522.	12.8	66
41	The FBXW2â€“MSX2â€“SOX2 axis regulates stem cell property and drug resistance of cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20528-20538.	7.1	63
42	The bone microenvironment increases phenotypic plasticity of ER+ breast cancer cells. Developmental Cell, 2021, 56, 1100-1117.e9.	7.0	63
43	Therapeutic potential of the dual EGFR/HER2Âinhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Research and Treatment, 2014, 144, 263-272.	2.5	49
44	Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clinical Cancer Research, 2021, 27, 4870-4882.	7.0	49
45	Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Research, 2015, 17, 3.	5.0	48
46	The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. British Journal of Cancer, 2019, 120, 331-339.	6.4	48
47	Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nature Medicine, 2018, 24, 505-511.	30.7	47
48	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast, 2017, 34, S19-S26.	2.2	46
49	Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Science Advances, 2020, 6, eabb2210.	10.3	46
50	Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers. Nature Communications, 2016, 7, 12991.	12.8	45
51	Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. Molecular Cancer Research, 2019, 17, 2318-2330.	3.4	41
52	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clinical Cancer Research, 2020, 26, 821-827.	7.0	40
53	Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Molecular Cancer Research, 2016, 14, 470-481.	3.4	39
54	A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer. Journal of Clinical Medicine, 2019, 8, 1772.	2.4	36

#	Article	IF	Citations
55	Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Research and Treatment, 2012, 134, 583-593.	2.5	31
56	AhR ligand aminoflavone suppresses Î±6â€integrinâ€“Srcâ€“Akt signaling to attenuate tamoxifen resistance in breast cancer cells. Journal of Cellular Physiology, 2019, 234, 108-121.	4.1	31
57	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clinical Cancer Research, 2020, 26, 738-745.	7.0	31
58	The Oncogenic STP Axis Promotes Triple-Negative Breast Cancer via Degradation of the REST Tumor Suppressor. Cell Reports, 2014, 9, 1318-1332.	6.4	24
59	Resistance to Anti-HER2 Therapies in Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e157-e164.	3.8	24
60	Photo activation of HPPH encapsulated in “Pocket” liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenografts. International Journal of Nanomedicine, 2015, 10, 125.	6.7	22
61	GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Research and Treatment, 2018, 170, 279-292.	2.5	22
62	Amplification of <i>TLK2</i> Induces Genomic Instability via Impairing the G2â€“M Checkpoint. Molecular Cancer Research, 2016, 14, 920-927.	3.4	21
63	PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells. Npj Breast Cancer, 2017, 3, 45.	5.2	21
64	Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. BMC Cancer, 2019, 19, 220.	2.6	19
65	Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). Breast Cancer Research, 2003, 5, 228-31.	5.0	18
66	Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. Breast Cancer Research, 2020, 22, 84.	5.0	18
67	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers, 2021, 13, 1458.	3.7	17
68	Interferon Signaling in Estrogen Receptorâ€“positive Breast Cancer: A Revitalized Topic. Endocrinology, 2022, 163, .	2.8	16
69	Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activity. Nucleic Acids Research, 2020, 48, 1800-1810.	14.5	15
70	A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2â€positive breast cancer. FASEB Journal, 2021, 35, e21719.	0.5	13
71	Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer. Clinical Breast Cancer, 2015, 15, 448-457.e2.	2.4	11
72	Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition. Molecular Cancer Therapeutics, 2018, 17, 921-930.	4.1	11

#	Article	IF	Citations
73	The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2020, 1863, 194631.	1.9	10
74	Management of hormone receptorâ€“positive, human epidermal growth factor 2â€“negative metastatic breast cancer. Breast Cancer Research and Treatment, 2021, 190, 189-201.	2.5	10
75	HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.. Journal of Clinical Oncology, 2018, 36, 509-509.	1.6	10
76	Elacestrant and the Promise of Oral SERDs. Journal of Clinical Oncology, 2022, 40, 3227-3229.	1.6	10
77	Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells. Cell and Bioscience, 2015, 5, 10.	4.8	9
78	Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine. Cancer Discovery, 2018, 8, 1352-1354.	9.4	7
79	NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. Scientific Reports, 2022, 12, 1972.	3.3	7
80	Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2. Cancer Cell, 2021, 39, 1302-1305.	16.8	6
81	Development of Acneiform Rash Does Not Predict Response to Lapatinib Treatment in Patients with Breast Cancer. Pharmacotherapy, 2013, 33, 1126-1129.	2.6	5
82	Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clinical Cancer Research, 2021, 27, 2648-2662.	7.0	4
83	Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. Npj Breast Cancer, 2021, 7, 63.	5.2	4
84	A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).. Journal of Clinical Oncology, 2020, 38, 1011-1011.	1.6	4
85	Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells. Cancers, 2022, 14, 2380.	3.7	4
86	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. Journal of Clinical Oncology, 2018, 36, 1025-1025.	1.6	3
87	A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2â€positive breast cancer. FASEB Journal, 2021, 35, .	0.5	2
88	In vivo longitudinal imaging of RNA interferenceâ€induced endocrine therapy resistance in breast cancer. Journal of Biophotonics, 2020, 13, e201900180.	2.3	1
89	Abstract 1077: Acquired neratinib resistance is associated with acquisition ofHER2andPIK3CAmutations and can be overcome using potent drug combinations in HER2-positive breast cancer models. , 2021, , .		1
90	Evaluation of tumor immune infiltrate as a determinant of response to neo-adjuvant lapatinib and trastuzumab (LT) in HER2-positive (+) breast cancer (BC).. Journal of Clinical Oncology, 2016, 34, 608-608.	1.6	1

#	Article	IF	Citations
91	Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer. Cancer Research, 2022, 82, PD8-06-PD8-06.	0.9	1
92	Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of <i>HER</i> and <i>PIK3CA</i> mutations and development of new treatment strategies and study models. Cancer Research, 2022, 82, P4-01-01-P4-01-01.	0.9	1
93	Abstract 930: Production of functionally active recombinant FOXA1: The first step towards targeted drug discovery. , 2021, , .		0
94	Crosstalk between PARP-1 and NF-Î°B signaling pathways as a potential determinant of PARPi sensitivity in trastuzumab resistant HER2+ breast cancer cell lines.. Journal of Clinical Oncology, 2015, 33, 606-606.	1.6	0
95	ADGRF1 signaling pathways in Breast Cancer. FASEB Journal, 2020, 34, 1-1.	0.5	0
96	DE-ESCALATING TREATMENT FOR HER2-POSITIVE EARLY BREAST CANCER. Transactions of the American Clinical and Climatological Association, 2020, 131, 119-126.	0.5	0
97	Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer. Cancer Research, 2022, 82, PD1-05-PD1-05.	0.9	0
98	Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial.. Journal of Clinical Oncology, 2022, 40, 522-522.	1.6	0